- Home
- CMMB vs SLGL Comparison
CMMB vs SLGL Comparison
Compare CMMB & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- SLGL
- Stock Information
- Founded
- CMMB 2004
- SLGL 1997
- Country
- CMMB Israel
- SLGL Israel
- Employees
- CMMB N/A
- SLGL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- SLGL Health Care
- Exchange
- CMMB Nasdaq
- SLGL Nasdaq
- Market Cap
- CMMB 23.0M
- SLGL 21.1M
- IPO Year
- CMMB N/A
- SLGL 2018
- Fundamental
- Price
- CMMB $1.32
- SLGL $7.21
- Analyst Decision
- CMMB Strong Buy
- SLGL Buy
- Analyst Count
- CMMB 2
- SLGL 1
- Target Price
- CMMB $8.50
- SLGL $40.00
- AVG Volume (30 Days)
- CMMB 109.4K
- SLGL 39.3K
- Earning Date
- CMMB 05-15-2025
- SLGL 05-23-2025
- Dividend Yield
- CMMB N/A
- SLGL N/A
- EPS Growth
- CMMB N/A
- SLGL N/A
- EPS
- CMMB N/A
- SLGL N/A
- Revenue
- CMMB N/A
- SLGL $12,103,000.00
- Revenue This Year
- CMMB N/A
- SLGL N/A
- Revenue Next Year
- CMMB N/A
- SLGL $31.17
- P/E Ratio
- CMMB N/A
- SLGL N/A
- Revenue Growth
- CMMB N/A
- SLGL 603.66
- 52 Week Low
- CMMB $0.78
- SLGL $3.34
- 52 Week High
- CMMB $2.55
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- CMMB 50.69
- SLGL 50.19
- Support Level
- CMMB $1.31
- SLGL $7.15
- Resistance Level
- CMMB $1.44
- SLGL $7.99
- Average True Range (ATR)
- CMMB 0.08
- SLGL 0.43
- MACD
- CMMB 0.00
- SLGL -0.13
- Stochastic Oscillator
- CMMB 54.55
- SLGL 27.59
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.